CARRA Elections Candidate Guide

Cross Cutting Committee Chair

Tova Ronis, MDCM
Children's National

The creation of the new CARRA Cross Cutting Committee is exciting to me as it encompasses reproductive health, transition, and mental health – all research areas that I am passionate about. Having this unique research committee will open up more avenues for research funding and successful completion of studies in these important areas.

I think that one of the main roles of the Chair and Vice Chair will be to communicate with the other Committees across CARRA so that all the relevant diseases are represented. It is important to ensure that all interested researchers have the opportunity to participate with the Committee. The Cross Cutting Committee is unique from other CARRA committees. There is potential for multidisciplinary collaboration, such as with other specialty groups, as well as the patient and family partnerships. Another major role of the leadership of this committee will be to support committee members to apply for and obtain funding to successfully complete their projects. I believe that it is important that trainees and early investigators be involved with all the collaborative projects that are planned. I am committed to continue to foster the culture of mentorship that I have experienced throughout my involvement with CARRA.

I have been organized and responsive in my role as CARRA Publications Committee chair and I will continue to use these organizational and communication skills if elected to chair the cross cutting disease committee. If elected, I would embrace the challenge of helping to build this new committee. My goal is to ensure the Cross Cutting Committee becomes a successful and productive Committee.

Finance Committee Member

Stacy Ardoin, MD, MS
Nationwide Children's Hospital/Columbus Children's

I am excited about the opportunity to serve on CARRA’s Finance Committee.  I have been an active CARRA member since I started my med/peds rheumatology fellowship in 2002, and it has been very exciting to see how CARRA has grown and matured into a large, dynamic research organization representing the vast majority of North American pediatric rheumatologists.

Through my involvement in CARRA as the SLE Committee Chair, CARRA Committee and Workgroup Task Force Chair, CARRA Annual Planning Committee Chair and Interim Chair of the new Cross Cutting Research Committee, I have learned a great deal about CARRA’s mission, structure, governance and vision.   I am interested to learn more about CARRA by serving on the Finance Committee.  Financial stability, longevity and strategy are crucial to CARRA’s ongoing success. 

As a clinical investigator, I have served as PI or co-investigator of several NIH, foundation and industry funded grants, and these experiences provide me with insight into the realities of funding a research organization.  As Division Chief at Nationwide Children’s Hospital and as the ACR’s Chair of the Special Committee on Pediatrics and Pediatric Rheumatology Symposium (PRSYM), I have garnered additional leadership experience which will serve me well on the Finance Committee.

CARRA requires strong financial footing in order to fund its mission to move pediatric rheumatology forward.  I am eager and excited to serve CARRA on the Finance Committee in order to do my part to assure CARRA’s sustainability and ongoing success.

John Bohnsack, MD
University of Utah Health Sciences Center

I have been a member of the CARRA Finance Committee for several years.  I recognize the need for sound financial controls in CARRA in order to maintain a sustainable mission based on the balance of its operating account, which in turn is based on an adequate flow of revenue, and the appropriate use of funds to support CARRA’s research mission. 

I have been an administrator in my Health Sciences Center at the system, department, division and individual level for most of my career.  Many of my responsibilities at the University of Utah include fiscal oversight, and I am quite comfortable that I have the knowledge and expertise to  contribute  to CARRA’s financial oversight.

I am firmly committed to the CARRA’s success, since I feel that the characterization and treatment of rare diseases is best carried out in consortiums.  I have been a member of CARRA since its inception, and have urged all of our faculty here at Utah to be engaged in its operations.  I am particularly pleased that CARRA provides the network to allow young faculty who have the desire to participate in research, to work on disease entities that would be difficult to carry out in a single institution.